Skip to main content
placeholder image

Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.

Journal Article


Abstract


Publication Date


  • 2022

Citation


  • Clingan, P. R., Brungs, D., Arnold, S., Coward, J., Fourie, S. J., Harris, D. L., . . . Desai, J. (2022). Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.. Journal of Clinical Oncology, 40(16_suppl), 9537. doi:10.1200/jco.2022.40.16_suppl.9537

Web Of Science Accession Number


Start Page


  • 9537

End Page


  • 9537

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


Publication Date


  • 2022

Citation


  • Clingan, P. R., Brungs, D., Arnold, S., Coward, J., Fourie, S. J., Harris, D. L., . . . Desai, J. (2022). Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.. Journal of Clinical Oncology, 40(16_suppl), 9537. doi:10.1200/jco.2022.40.16_suppl.9537

Web Of Science Accession Number


Start Page


  • 9537

End Page


  • 9537

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication